Atherosclerosis and Lipoproteins |
From the Cell Biology Laboratory, Division of Stroke and Vascular Disease, St Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada; the Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada; and the Department of Microbiology (G.Z.), University of Texas Health Science Center at San Antonio, TX.
Correspondence to Dr Grant N. Pierce, Division of Stroke and Vascular Disease, Saint Boniface General Hospital Research Centre, 351 Tache Ave, Winnipeg, Manitoba, Canada R2H 2A6. E-mail gpierce{at}sbrc.ca
Objective Our study tested the hypothesis that the mitogenic effect of oxidized low-density lipoprotein (oxLDL) on vascular cells may be further enhanced by the presence of cytokines and growth factors known to be present in the atherosclerotic environment.
Methods and Results Quiescent fibroblasts and vascular smooth muscle cells were treated with 10 or 50 µg/mL minimally-oxidized LDL in combination with serum for 24 or 48 hours. Surprisingly, these cells showed inhibited release from growth arrest and a significant reduction in the number of cells completing the cell cycle when compared with cells treated with serum alone. This was not due to an induction of apoptosis. The antiproliferative effects were not closely associated with changes in the expression of cell cycle proteins. Instead, oxLDL inhibited the translocation of cell cycle proteins cell division cycle (Cdc) 2, cyclin-dependent kinase (Cdk) 2, Cdk 4, Cyclin A, Cyclin B1, Cyclin D1, and proliferative cell nuclear antigen (PCNA) into the nucleus, as compared with separate treatments with serum alone. Kinase activation associated with specific cell cycle proteins was also inhibited by oxLDL.
Conclusions oxLDL, in the presence of serum, has a surprising inhibitory effect on cell proliferation that occurs through an inhibition of import of cell cycle proteins into the cell nucleus.
Key Words: atherosclerosis cyclin kinase, cyclin-dependent cell proliferation
This article has been cited by other articles:
![]() |
M. N. Chahine and G. N. Pierce Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions Pharmacol. Rev., September 1, 2009; 61(3): 358 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Faustino, P. Cheung, M. N. Richard, E. Dibrov, A. L. Kneesch, J. F. Deniset, M. N. Chahine, K. Lee, D. Blackwood, and G. N. Pierce Ceramide regulation of nuclear protein import J. Lipid Res., March 1, 2008; 49(3): 654 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Apostolov, A. G. Basnakian, X. Yin, E. Ok, and S. V. Shah Modified LDLs induce proliferation-mediated death of human vascular endothelial cells through MAPK pathway Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1836 - H1846. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. X.-F. Deng, J. M. Spin, A. Tsalenko, A. Vailaya, A. Ben-Dor, Z. Yakhini, P. Tsao, L. Bruhn, and T. Quertermous Molecular Signatures Determining Coronary Artery and Saphenous Vein Smooth Muscle Cell Phenotypes: Distinct Responses to Stimuli Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1058 - 1065. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |